FMFrancesca Micci

Francesca Micci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesca Micci has a total of 128 co-authors. Here are the top co-authors by number of shared publications:

  • Sverre Heim

    Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

    30 shared publications
  • Ben Davidson

    Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway

    14 shared publications
  • Ioannis Panagopoulos

    Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

    14 shared publications
  • Ioannis Panagopoulos

    Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway

    13 shared publications
  • Antonio Agostini

    Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

    10 shared publications
  • Marta Brunetti

    Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway

    10 shared publications

Latest Publications

  • Uterine Sarcomas With KDM2B Fusion: Clinicopathological Analysis of Three Cases Supporting a Novel BCOR-Altered Entity

    by Pavel Dundr, Jan Novotný, Ben Davidson, Francesca Micci, Marcin Jedryka, Tymoteus Poprawski, Michaela Kendall Bártů, Jitka Hausnerová, Michaela Koblížková, Radoslav Matěj, et al.

    High-grade endometrial stromal sarcomas (HGESS) with BCOR-alteration include sarcomas with YWHAE::NUTM2A/B fusion, ZC3H7B::BCOR fusion, BCOR -ITD, BCOR alternative fusion, and BCORL1 fusion. Recently, 4 cases of uterine sarcomas with KDM2B fusion have been described, which were suggested to belong to the category of BCOR-altered tumors. These tumors are characterized by recurrent fusions of the KDM2B gene with fusion partners including EPC1 , EP400 , and CITED1 . Morphologically, some of them may have a nonspecific spindle-cell or round-cell appearance. In other tumors, however, peculiar morphologic features combining atypical round cells with at least focal sex cord-like features and myxoid stroma were found. In our study, we described 3 additional cases of uterine sarcomas with KDM2B fusion, with fusion partners including EPC1 , EPC2 , and CREBBP . Morphologically, these tumors showed either pure spindle-cell morphology, a combination of spindle and round cells, or a heterogeneous pattern with spindle cells, round cells, and prominent hyalinization, with only focal, vague sex cord-like features. Despite possible morphologic overlap with low-grade endometrial stromal sarcomas in some cases, these tumors seem to represent a variant of HGESS belonging to the category of BCOR-altered sarcomas and have a propensity for aggressive behavior, as 2 of our patients died of disease, and the third had pelvic recurrence before being lost to follow-up.

  • Open Access

    Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile

    by Marta Brunetti, Ioannis Panagopoulos, Valeria Vitelli, Kristin Andersen, Tarjei S. Hveem, Ben Davidson, Ane Gerda Z. Eriksson, Pernille Kristina Bjerre Trent, Sverre Heim, Francesca Micci

    Endometrial carcinomas (ECs) are histologically classified as endometrioid and nonendometrioid tumors, with each subgroup displaying different molecular profiles and clinical outcomes. Considerable biological and clinical heterogeneity exists within this scheme, however, reflecting its imperfection. We aimed to gather additional data that might help clarify the tumors’ pathogenesis and contribute toward a more meaningful classification scheme. In total, 33 ECs were examined for the presence of chromosomal aberrations, genomic imbalances, pathogenic variants, microsatellite instability, and expression profiles at both gene and miRNA levels. Chromosome 1 was the most frequently rearranged chromosome, showing a gain of all or part of the long arm. Pathogenic variants were found for PTEN (53%), PDGFRA (37%), PIK3CA (34%), and KIT (31%). High microsatellite instability was identified in 15 ECs. Comparing tumors and controls, we identified 23 differentially expressed genes of known importance in carcinogenesis, 15 genes involved in innate and adaptative immune responses, and altered expression of 7 miRNAs. miR-32-5p was the most upregulated. Our series showed a high degree of heterogeneity. Tumors were well-separated from controls, but there was no clear-cut separation between endometrioid and nonendometrioid ECs. Whether this means that the current phenotypic classification is of little relevance or if one still has not detected which genomic parameters to enter into correlation analyses remains unknown.


  • Open Access

    Cytogenetic and molecular analyses of 291 gastrointestinal stromal tumors: site-specific cytogenetic evolution as evidence of pathogenetic heterogeneity

    by Ludmila Gorunova, Kjetil Boye, Ioannis Panagopoulos, Jeanne-Marie Berner, Bodil Bjerkehagen, Ivar Hompland, Ingvild Lobmaier, Toto Hølmebakk, Tarjei S. Hveem, Sverre Heim, et al.

    Https://doi.org/10.18632/oncotarget.28209 Ludmila Gorunova, Kjetil Boye, Ioannis Panagopoulos, Jeanne-Marie Berner, Bodil Bjerkehagen, Ivar Hompland, Ingvild Lobmaier, Toto Hølmebakk, Tarjei S....


  • Open Access

    Molecular pathogenesis and prognostication of "low‐grade'' and "high‐grade" endometrial stromal sarcoma

    by Francesca Micci, Sverre Heim, Ioannis Panagopoulos

    Endometrial stromal sarcomas (ESS) are a heterogeneous group of rare mesenchymal cancers. Considerable knowledge has been gained in recent years about the molecular characteristics of these cancers, which helps to classify them in a more meaningful manner leading to improved diagnosis, prognostication, and treatment. According to this classification, ESS is now grouped as low‐ or high‐grade. ESS may have overlapping clinical presentation, morphology, and immunohistochemical profile. Their genetic characteristics allow subdivision of many of them depending on which pathogenetically important fusion genes they carry, but clearly much more needs to be unraveled in this regard. We here provide an overview of the molecular pathogenetic knowledge gained so far on low‐ and high‐grade ESS.


  • Open Access

    Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer

    by Marta Brunetti, Ioannis Panagopoulos, Ilyá Kostolomov, Ben Davidson, Sverre Heim, Francesca Micci

    Ovarian carcinomas and carcinosarcomas often cause malignant effusions, an accumulation within serous cavities of fluid containing cancer cells. Few studies have focused on the molecular alterations and genetic mechanisms behind effusion formation. The present study investigated the mutation status of TP53, PIK3CA, KRAS, HRAS, NRAS and BRAF in effusion fluids from 103 patients with ovarian cancer. In addition, array Comparative Genomic Hybridization (aCGH) analysis was performed on 20 effusions from patients with high‑grade serous carcinoma (10 cases positive for TP53 mutation and 10 with TP53 wild‑type). TP53 mutations, two of which were novel: c.826_830delCCTGT and c.475_476GC>TT, were identified in 44% of the cases. Mutations in KRAS, HRAS, and PIK3CA were identified in two, two and four cases, respectively. None of the effusions analysed showed NRAS or BRAF mutations. The aCGH analysis revealed highly imbalanced genomes similar to those described in primary ovarian carcinomas. No specific profile was indicated to distinguish tumors with TP53 mutations from those without. The molecular profiling of cells found in effusion fluids from patients with ovarian cancer thus showed considerable molecular heterogeneity. TP53 seems to be the most frequently mutated gene in these cells and may serve a leading role in the metastatic process.


  • Open Access

    Molecular characterization of carcinosarcomas arising in the uterus and ovaries

    by Marta Brunetti, Antonio Agostini, Julie Staurseth, Ben Davidson, Sverre Heim, Francesca Micci

    Molecular characterization of carcinosarcomas arising in the uterus and ovaries


  • Open Access

    Novel GTF2I–PDGFRB and IKZF1–TYW1 fusions in pediatric leukemia with normal karyotype

    by Ioannis Panagopoulos, Marta Brunetti, Margrethe Stoltenberg, Rønnaug A. U. Strandabø, Julie Staurseth, Kristin Andersen, Ilyá Kostolomov, Tarjei S. Hveem, Susanne Lorenz, Tove Anita Nystad, et al.

    Many cases of acute lymphoblastic leukemia (ALL) carry visible acquired chromosomal changes of pathogenetic, diagnostic, and prognostic importance. Nevertheless, from one-fourth to half of newly diagnosed ALL patients have no visible chromosomal changes detectable by G-banding analysis at diagnosis. The introduction of powerful molecular methodologies has shown that many karyotypically normal ALLs carry clinically important submicroscopic aberrations. We used fluorescence in situ hybridization (FISH), array comparative genomic hybridization (aCGH), RNA sequencing, reverse transcription (RT) and genomic polymerase chain reaction (PCR), as well as Sanger sequencing to investigate a case of pediatric ALL with a normal karyotype. FISH with a commercial PDGFRB breakapart probe showed loss of the distal part of the probe suggesting a breakpoint within the PDGFRB locus. aCGH revealed submicroscopic deletions in chromosome bands 5q32q35.3 (about 30 Mb long, starting within PDGFRB and finishing in the CANX locus), 7q34 (within TCRB), 9p13 (PAX5), 10q26.13 (DMBT1), 14q11.2 (TRAC), and 14q32.33 (within the IGH locus). RNA sequencing detected an in-frame GTF2I–PDGFRB and an out-of-frame IKZF1–TYW1 fusion transcript. Both fusion transcripts were verified by RT-PCR together with Sanger sequencing and interphase FISH. The GTF2I–PDGFRB fusion was also verified by genomic PCR and FISH. The corresponding GTF2I–PDGFRB fusion protein would consist of almost the entire GTF2I and that part of PDGFRB which harbors the catalytic domain of the tyrosine kinase. It would therefore seem to lead to abnormal tyrosine kinase activity in a manner similar to what has been seen for other PDGFRB fusion proteins. The examined pediatric leukemia is a Ph-like ALL which carries novel GTF2I–PDGFRB and IKZF1–TYW1 fusion genes together with additional submicroscopic deletions. Because hematologic neoplasms with PDGFRB-fusion genes can be treated with tyrosine kinase inhibitors, the detection of such novel fusions may be clinically important. Since the GTF2I–PDGFRB could be detected only after molecular studies of the leukemic cells, further investigations of ALL-cases, perhaps especially but not exclusively with a normal karyotype, are needed in order to determine the frequency of GTF2I–PDGFRB in leukemia, and also to find out which clinical impact the fusion may have.


  • Open Access

    The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas

    by Antonio Agostini, Marta Brunetti, Ben Davidson, Claes G. Tropé, Ane Gerda Z. Eriksson, Sverre Heim, Ioannis Panagopoulos, Francesca Micci

    Different microRNAs are dysregulated in ovarian cancer where some of them have proved to be valid biomarkers. miRNA profiling analyses have shown that the different histotypes of ovarian carcinoma display differential expression of specific miRNAs. In the present study, we used miRNA-sequencing and Real-Time qPCR to detect the expression levels of miRNAs belonging to the miRNA-192/215 family, namely miR-192, miR-194, and miR-215, in different types of ovarian neoplasia, finding that miR-192, miR-194, and miR-215 were upregulated in ovarian carcinomas of the mucinous subtype, but downregulated in other types of carcinoma and in sex cord-stromal tumors. The expression of the said miRNAs was 6-fold higher in mucinous tumors compared to the other histotypes making them candidates for a possible role as diagnostic biomarkers.


  • Open Access

    Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas

    by Antonio Agostini, Marta Brunetti, Ben Davidson, Claes Göran Tropé, Sverre Heim, Ioannis Panagopoulos, Francesca Micci

    Formation of fusion genes is pathogenetically crucial in many solid tumors. They are particularly characteristic of several mesenchymal tumors, but may also be found in epithelial neoplasms. Ovarian carcinomas, too, may harbor fusion genes but only few of these were found to be recurrent with a rate ranging from 0.5 to 5%. Because most attempts to find specific and recurrent fusion transcripts in ovarian carcinomas focused exclusively on high‐grade serous carcinomas, the situation in the other carcinoma subgroups remains largely uninvestigated as far as fusion genes are concerned. We performed transcriptome sequencing on a series of 34 samples from ovarian tumors that included borderline, clear cell, mucinous, endometrioid, low‐grade and high‐grade serous carcinomas in search of fusion genes typical of these subtypes. We found a total of 24 novel fusion transcripts. The PCMTDI‐CCNL2 fusion transcript, which involves a member of the cyclin family, was found recurrently involved but only in endometrioid carcinomas (4 of 18 tumors; 22%). We also found three additional fusion transcripts involving genes belonging to the cyclin family: ANXA5‐CCNA2 and PDE4D‐CCNB1 were detected in two endometrioid carcinomas, whereas CCNY‐NRG4 was identified in a clear cell carcinoma. The recurrent involvement of CCNL2 in four fusions and of three other genes of the cyclin family in three additional transcripts hints that deregulation of cyclin genes is important in the pathogenesis of ovarian carcinomas in general but of endometrioid carcinomas particularly.


  • Open Access

    Identification of anEPC2-PHF1fusion transcript in low-grade endometrial stromal sarcoma

    by Marta Brunetti, Ludmila Gorunova, Ben Davidson, Sverre Heim, Ioannis Panagopoulos, Francesca Micci

    Identification of an EPC2-PHF1 fusion transcript in low-grade endometrial stromal sarcoma Identification of an EPC2-PHF1 fusion transcript in low-grade endometrial stromal sarcoma